Healio

Spiriva Respimat safe, tolerable as add-on therapy in adolescents with asthma

Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — Once-daily tiotropium bromide as an add-on to inhaled corticosteroid therapy demonstrated ...
Monthly Prescribing Reference

Spiriva Respimat Approved for COPD Maintenance

Tiotropium as Asthma Add-On Treatment Shows Promise Boehringer Ingelheim announced that the Food and Drug Administration (FDA) has approved Spiriva Respimat (tiotropium bromide) inhalation spray for ...
Medscape

FDA OKs Mist Spray Form of Tiotropium (Spiriva Respimat)

The US Food and Drug Administration (FDA) yesterday approved an inhalation spray version of tiotropium bromide (Spiriva Respimat, Boehringer Ingelheim) for maintenance treatment of chronic obstructive ...
Healio

FDA to review new drug application for Spiriva Respimat for asthma

Please provide your email address to receive an email when new articles are posted on . Boehringer Ingelheim Pharmaceuticals announced that the FDA has agreed to review its new drug application for ...
FiercePharma

Phase III results: tiotropium* Respimat® is effective in symptomatic asthma patients irrespective of their allergic status

SAN ANTONIO, Texas--(BUSINESS WIRE)--Tiotropium delivered once daily via Respimat™ significantly improved lung function and reduced asthma exacerbations in patients who remain symptomatic despite ...
Monthly Prescribing Reference

Spiriva Respimat Gains Indication and New Dosage Strength

Boehringer Ingelheim announced that Spiriva Respimat (tiotropium bromide) is now available for the long-term maintenance treatment of asthma in patients ages ≥12 years. Boehringer Ingelheim announced ...
Business Wire

Tiotropium Respimat

LONDON & INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim announced today new study results from the Phase III CanoTinA-asthma ® trial that showed adding tiotropium Respimat ® to maintenance ...
PharmaTimes

BI boosted by strong Spiriva Respimat data

Boehringer vigorously defended Respimat at the time, pointing out that the findings of the pooled data were flawed. Commenting on TIOSPIR, Richard Russell of the Wexham Park Hospital in the UK, said ...
elEconomista

New data show benefit of tiotropium/olodaterol Respimat® from the start of COPD maintenance therapy 1,2,3

Boehringer Ingelheim today announced new data analyses from the pivotal Phase III TONADO ® 1&2 studies 4 (NCT01431274/NCT01431287). Data showed tiotropium/olodaterol ...
Business Wire

FDA approves Boehringer Ingelheim’s Stiolto™ * Respimat ® as once-daily maintenance treatment for COPD

INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved once-daily Stiolto™ Respimat ® (tiotropium bromide and olodaterol) ...
elEconomista

Tiotropium Respimat® improved lung functionin children with asthma aged 6-17 and is well-tolerated compared toplacebo in children aged 1-171-5

Boehringer Ingelheim announced today new study results from the Phase III CanoTinA-asthma ® trial that showed adding tiotropium Respimat ® to maintenance asthma therapy significantly improved lung ...
Finanznachrichten

Landmark TIOSPIR' trial demonstrates comparable long-term safety of tiotropium delivered via Respimat and HandiHaler in COPD patients

The three-year TIOSPIR ' trial showed both tiotropium Respimat ® doses to be non-inferior to Spiriva ® HandiHaler ® (tiotropium bromide inhalation powder) with comparable impact on all-cause mortality ...